Kenichi Harada

9PUBLICATIONS
19CO-AUTHORS
Cancer therapy (excl. chemotherapy and radiation therapy)Predictive and prognostic markersMolecular targets
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (9)

|Jun 22, 2023
Efficacy and safety of pembrolizumab and axitinib as first-line treatment for patients with advanced renal cell carcinoma: Real-world experience in Japan.

Ken-Ichi Harada, Ryo Sato, Yukari Bando

|Jun 15, 2023
The poor antitumor effect of pembrolizumab in advanced upper urothelial carcinoma with renal parenchymal invasion.

Takuto Hara, Junya Furukawa, Yasuyoshi Okamura

|May 02, 2023
Impact of cytoreductive nephrectomy prior to combination therapy of ipilimumab plus nivolumab in metastatic renal cell carcinoma.

Takuto Hara, Junya Furukawa, Yusuke Shiraishi

|Dec 28, 2022
Significance of second progression-free survival in patients with advanced urothelial cancer who received platinum-based combination chemotherapy followed by pembrolizumab.

Ryo Sato, Teruo Inamoto, Yuto Matsushita

|Sep 07, 2022
Predictive factors for the effectiveness of novel androgen receptor axis-targeted agents in patients with metastatic prostate cancer.

Nishimoto Koshiro, Kenichi Nakajima, Masafumi Oyama

|Jul 07, 2022
Association between sarcopenia based on psoas muscle index and the response to nivolumab in metastatic renal cell carcinoma: A retrospective study.

Hideto Ueki, Takuto Hara, Yasuyoshi Okamura

Pageof 2

Frequent Collaborators

4 joint publications

Naohiro Fujimoto

4 joint publications

Yukari Bando

4 joint publications

Tomoaki Terakawa

4 joint publications

Takuto Hara